BACKGROUND:Older blacks are less likely to receive guideline-recommended antilipemic therapy and achieve lipid control than older whites because, in part, of out-of-pocket costs. We sought to determine whether racial differences in antilipemic use and lipid control narrowed after Medicare Part D's implementation. METHODS: This before-after study included 1,091 black and white adults 70 years or older with coronary heart disease and/or diabetes mellitus from the Health Aging and Body Composition Study. Primary outcomes were antilipemic use and low-density lipoprotein cholesterol control. Key independent variables were race, time (pre-Part D vs post-Part D), and their interaction. RESULTS: Before Part D, fewer blacks than whites reported taking an antilipemic (32.70% vs 49.35%), and this difference was sustained after Part D (blacks 48.30% vs whites 64.57%). Multivariable generalized estimating equations confirmed no post-Part D change in racial differences in antilipemic use (adjusted ratio of the odds ratio 1.07, 95% CI 0.79-1.45). Compared with whites, more blacks had poor lipid control both before Part D (24.30% vs 12.36%, respectively) and after Part D (24.46% vs 13.72%, respectively), with no post-Part D change in racial differences in lipid control (adjusted ratio of the odds ratio 0.82, 95% CI 0.51-1.33). CONCLUSION: Although antilipemic use increased after Medicare Part D for both races, this policy change was associated with a change neither in lipid control for either racial group nor in the racial differences in antilipemic use or lipid control.
RCT Entities:
BACKGROUND: Older blacks are less likely to receive guideline-recommended antilipemic therapy and achieve lipid control than older whites because, in part, of out-of-pocket costs. We sought to determine whether racial differences in antilipemic use and lipid control narrowed after Medicare Part D's implementation. METHODS: This before-after study included 1,091 black and white adults 70 years or older with coronary heart disease and/or diabetes mellitus from the Health Aging and Body Composition Study. Primary outcomes were antilipemic use and low-density lipoprotein cholesterol control. Key independent variables were race, time (pre-Part D vs post-Part D), and their interaction. RESULTS: Before Part D, fewer blacks than whites reported taking an antilipemic (32.70% vs 49.35%), and this difference was sustained after Part D (blacks 48.30% vs whites 64.57%). Multivariable generalized estimating equations confirmed no post-Part D change in racial differences in antilipemic use (adjusted ratio of the odds ratio 1.07, 95% CI 0.79-1.45). Compared with whites, more blacks had poor lipid control both before Part D (24.30% vs 12.36%, respectively) and after Part D (24.46% vs 13.72%, respectively), with no post-Part D change in racial differences in lipid control (adjusted ratio of the odds ratio 0.82, 95% CI 0.51-1.33). CONCLUSION: Although antilipemic use increased after Medicare Part D for both races, this policy change was associated with a change neither in lipid control for either racial group nor in the racial differences in antilipemic use or lipid control.
Authors: Yuting Zhang; Judith R Lave; Joseph P Newhouse; Julie M Donohue Journal: J Gerontol B Psychol Sci Soc Sci Date: 2009-12-14 Impact factor: 4.077
Authors: Julie M Donohue; Yuting Zhang; Judith R Lave; Walid F Gellad; Aiju Men; Subashan Perera; Joseph T Hanlon Journal: Am Heart J Date: 2010-07 Impact factor: 4.749
Authors: Dima M Qato; Stacy Tessler Lindau; Rena M Conti; L Philip Schumm; G Caleb Alexander Journal: Pharmacoepidemiol Drug Saf Date: 2010-08 Impact factor: 2.890
Authors: L V Franse; M Di Bari; R I Shorr; H E Resnick; J T van Eijk; D C Bauer; A B Newman; M Pahor Journal: Diabetes Care Date: 2001-12 Impact factor: 19.112
Authors: Zachary A Marcum; Yan Zheng; Subashan Perera; Elsa Strotmeyer; Anne B Newman; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Julie M Donohue; Joseph T Hanlon Journal: Res Social Adm Pharm Date: 2013-01-04
Authors: Julie M Donohue; Yuting Zhang; Men Aiju; Subashan Perera; Judith R Lave; Joseph T Hanlon; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2011-12 Impact factor: 4.105
Authors: James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp Journal: Lancet Date: 2002-11-23 Impact factor: 79.321
Authors: Zachary A Marcum; Joseph T Hanlon; Elsa S Strotmeyer; Anne B Newman; Ronald I Shorr; Eleanor M Simonsick; Douglas C Bauer; Robert Boudreau; Julie M Donohue; Subashan Perera Journal: J Am Geriatr Soc Date: 2014-10-03 Impact factor: 5.562
Authors: Sara M Sarasua; Jiexiang Li; German T Hernandez; Keith C Ferdinand; Jonathan N Tobin; Kevin A Fiscella; Daniel W Jones; Angelo Sinopoli; Brent M Egan Journal: J Clin Hypertens (Greenwich) Date: 2017-05-07 Impact factor: 3.738
Authors: Luisa Arueira Chaves; Danielle Maria de Souza Serio Dos Santos; Monica Rodrigues Campos; Vera Lucia Luiza Journal: Public Health Rev Date: 2019-12-09